Singular Genomics Systems (OMIC)
(Delayed Data from NSDQ)
$5.65 USD
-0.02 (-0.26%)
Updated Sep 12, 2024 02:25 PM ET
After-Market: $9.39 +3.74 (66.19%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Singular Genomics Systems, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 3 | 1 | 0 | 0 | 0 |
Cost Of Goods | 3 | 1 | 0 | 0 | 0 |
Gross Profit | -1 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 102 | 93 | 61 | 28 | 13 |
Income After Depreciation & Amortization | -103 | -93 | -61 | -28 | -13 |
Non-Operating Income | 9 | 3 | -37 | 0 | 0 |
Interest Expense | 1 | 1 | 1 | 1 | 0 |
Pretax Income | -95 | -91 | -99 | -28 | -12 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -95 | -91 | -99 | -28 | -12 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -95 | -91 | -99 | -28 | -12 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -97 | -87 | -58 | -27 | -12 |
Depreciation & Amortization (Cash Flow) | 6 | 7 | 3 | 1 | 0 |
Income After Depreciation & Amortization | -103 | -93 | -61 | -28 | -13 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 2.42 | 2.37 | 1.57 | NA | NA |
Diluted EPS Before Non-Recurring Items | -39.04 | -38.44 | -47.75 | NA | NA |
Diluted Net EPS (GAAP) | -39.04 | -38.44 | -63.06 | -79.28 | NA |
Fiscal Year end for Singular Genomics Systems, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.74 | 0.44 | 1.08 | 0.46 | 0.51 |
Cost Of Goods | 0.92 | 0.86 | 1.54 | 0.53 | 0.60 |
Gross Profit | -0.18 | -0.42 | -0.46 | -0.07 | -0.09 |
SG&A, R&D, and Dept/Amort Expenses | 22.63 | 26.43 | 24.82 | 24.47 | 27.51 |
Income After SG&A, R&D, and Dept/Amort Expenses | -22.81 | -26.85 | -25.28 | -24.54 | -27.60 |
Non-Operating Income | 1.84 | 2.11 | 2.32 | 2.46 | 2.30 |
Interest Expense | 0.29 | 0.28 | 0.29 | 0.29 | 0.27 |
Pretax Income | -21.25 | -25.02 | -23.25 | -22.36 | -25.58 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -21.25 | -25.02 | -23.25 | -22.36 | -25.58 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -21.25 | -25.02 | -23.25 | -22.36 | -25.58 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 2.48 | 2.46 | 2.45 | 2.44 | 2.42 |
Diluted EPS Before Non-Recurring Items | -8.57 | -10.21 | -9.61 | -9.31 | -10.51 |
Diluted Net EPS (GAAP) | -8.57 | -10.21 | -9.31 | -9.31 | -10.51 |